Next Generation Protein Therapeutics
Parc 55 Hilton
55 Cyril Magnin St
San Francisco, , CA
IBC Life Sciences
Next Generation Protein Therapeutics
Parc 55 Hilton
San Francisco

Schedule of Presentations:

Monday, May 18, 2015
07:00:00 Registration and Coffee
08:00:00 Chairperson's Remarks Jennifer Cochran
08:15:00 Potent Antibody Drug Conjugates for Cancer Therapy Peter D Senter
08:45:00 Bispecific Antibodies - Are We There Yet? Paul J. Carter
09:15:00 New Engineering and Application Perspectives of Scaffold Proteins Andreas Plückthun
09:45:00 Networking Refreshment Break in Poster and Exhibit Hall
10:10:00 Chairperson's Remarks Jennifer Cochran
10:15:00 Integrin-targeted Cancer Immunotherapy Karl Dane Wittrup
10:45:00 Manipulation of the Immune Response To Cancer Through Inhibition of the PD-1 Pathway Gary FeldwischStarling
11:15:00 An Alternative Platform for Fusing Cytokines to Antibodies Stephen Gillies
11:45:00 Tumor-Targeted Drug Delivery Via XTEN™, A Protein-Polymer Offering Precisely Controlled Structure and Valency Volker Schellenberger
12:15:00 Networking Luncheon in Poster and Exhibit Hall
13:25:00 Chairperson's Remarks Manuel Baca
13:30:00 The Role of NGS and In Vitro Selection for Hit Identification and Optimization at BMS
14:00:00 Next-Generation Sequencing and Protein Mass Spectrometry for the Comprehensive Analysis of Human Cellular and Serum Antibody Repertoires Gregory C. Ippolito
14:30:00 Applying Deep Sequencing to Antibody Selections Andrew Bradbury
15:00:00 Networking Refreshment Break in Poster & Exhibit Hall
15:30:00 A New Technology Platform that Enables High-Throughput Analysis and Engineering of Antibodies, Biosensors, and Enzymes Jennifer Cochran
16:00:00 Protease-Resistant Human IgGs, Novel Antibodies with Novel Properties for Treatment of Cancers and Infectious Disease Agents William R. Strohl
16:30:00 Engineering Albumin to Tailor Half-Life and Improve Efficacy of Protein Drugs
17:00:00 Networking Cocktail Reception in Poster and Exhibit Hall
18:00:00 Dinner Discussions Paul Watt, Arne Skerra, Bob Lutz, Alan C Rigby, Alan Dickson, Leonard Dane P. Freedman, Volker Schellenberger
Tuesday, May 19, 2015
07:30:00 Coffee Break
08:00:00 Chairperson's Remarks Robert Mabry
08:15:00 Phylomer Derived Cell Penetrating Peptides Facilitate More Efficient Delivery of Peptides and Proteins to the Cytoplasm Paul Watt
08:15:00 Adnectins in Engineered, Multi-Component Biologics Dasa Lipovsek
08:45:00 Orally Delivered and Injected Constrained Peptides for Inflammatory Bowel Disease Mark Smythe
08:45:00 Targeted Depletion of Pathogenic T Cells for the Therapy of Chronic Inflammatory Diseases
09:15:00 Discovery and Development of Unnatural Peptide Drugs
09:15:00 In Vitro V(D)J Recombination: A Robust Strategy for Generating Fully Human Agonist and Antagonist Antibodies to GPCRs Michael Gallo
09:45:00 Networking Refreshment Break in Poster and Exhibit Hall
10:30:00 Venoms to Drugs: Harnessing Disulfide-Rich Peptides from Venomous Animals to Target Neuronal Ion Channels Involved in Human Disease Glenn F. King
10:30:00 Creating Biologics that Cross the Blood-Brain Barrier using a Peptide Conjugation Strategy Jean Lachowicz
11:00:00 Precision Delivery of Biologics into the Cytosol of Cells Bradley L. Pentelute
11:00:00 GPCR Structure Guided Drug Discovery
11:30:00 Spotlight Presentation
12:00:00 Networking Luncheon in Poster and Exhibit Hall
13:25:00 Chairperson's Remarks Dimiter Dimitrov
13:30:00 Overcome Key Challenges in Antibody Drug Conjugate Design through the SMARTag Technology Platform
14:00:00 De-risking ADC Development Through Cell-free Based Rapid Make-test Cycles
14:30:00 Site-specific Conjugation Through Carbohydrates Dimiter Dimitrov
15:00:00 Networking Refreshment Break and Last Chance for Poster and Exhibit Viewing
15:45:00 Clinical Development of ADCs Lessons Learned and Where Do We Go From Here Bob Lutz
16:15:00 PEG Alternatives - New Applications of PASylation for Therapeutic Protein Development Arne Skerra
16:45:00 Close of Tuesday Sessions
Wednesday, May 20, 2015
07:30:00 Coffee
08:00:00 Chairperson's Remarks Arne Skerra
08:15:00 Development of Bite® Antibody Construct Blinatumomab - The First FDA-Approved Bispecific Antibody Patrick Baeuerle
08:45:00 Engineered Proteins for Signaling Jim Wells
09:15:00 Receptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings Mark Dennis
09:45:00 Networking Refreshment Break
10:15:00 An Open Cell Free Protein Synthesis Platform to Discover Novel Antibodies and Bispecifics Aaron K. Sato
11:15:00 Engineering Novel Bispecific Antibody/Fusion Protein for Enhanced Biological Activity Zhenping Zhu
11:45:00 Technology Workshop Presentations
12:15:00 Lunch on your Own
13:25:00 Chairperson's Remarks H. Kaspar Binz
13:30:00 Closing in Cancer Using Multi-Specific DARPins Kaspar Binz
14:00:00 CD3-Folate Bioconjugates for the Treatment of Ovarian Cancer
14:30:00 Improving the Developability of a Bispecific Scaffold with Protein Design
15:00:00 Roundtable Discussions & Networking Refreshment Break
15:30:00 Nanobodies as a Versatile and Clinically Validated Approach for Multi-Specifics Antonin de Fougerolles
16:00:00 Discovery and Characterization of COVA322 - A Clinical-Stage Bispecific TNF/IL-17A Inhibitor
16:30:00 Engineered Affibody-Based Ligand-Trap that Block IL-17 with Unparalleled In Vivo Potency Joachim Feldwisch
17:00:00 Close of Conferences
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.